cGAS-STING and PD1/PDL-1 pathway in breast cancer: a window to new therapies

References

• Ibrahimi M, Jamalzei B, Akbari M, et al. Association between interleukin 4 (IL-4) VNTR, gene polymorphism, and breast cancer susceptibility in Iranian population: experimental and web base analysis. Bratisl Lek Listy. 2018;119(10):651–654. doi: 10.4149/BLL_2018_116.
   PubMed Web of Science ®Google Scholar
• Ibrahimi R, Ibrahimi M, Jamalzei B, et al. Association between interleukin‐1 receptor antagonist (IL‐1ra) VNTR, gene polymorphism and breast cancer susceptibility in Iranian population: experimental and web‐based analysis. Int J Immunogenet. 2022;49(4):254–259. doi: 10.1111/iji.12584.
   PubMed Web of Science ®Google Scholar
• Mokashi AA, Bhatia NM. Bioactive natural products for breast cancer chemoprevention and treatment. CBC. 2023;19(10):38–67. doi: 10.2174/1573407219666230529151351.
   Google Scholar
• Genel ME, Adacan K, Selvi S, et al. Apoptosis-inducing, anti-angiogenic and anti-migratory effects of a dinuclear Pd (II) complex on breast cancer: a promising novel compound. Microvasc Res. 2024;151:104619. doi: 10.1016/j.mvr.2023.104619.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhong Y. Breast cancer immunotherapy. Cell Mol Immunol. 2004;1(4):247–255.
   PubMed Web of Science ®Google Scholar
• Debien V, De Caluwé A, Wang X, et al. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023;9(1):7. doi: 10.1038/s41523-023-00508-3.
   PubMed Web of Science ®Google Scholar
• Moossavi M, Shojaee M, Musavi M, et al. The polymorphism of miR-146a (rs2910164) and breast cancer risk: a Meta-Analysis of 17 studies. Microrna. 2020;9(4):310–320. doi: 10.2174/2211536609666201125115019.
   PubMedGoogle Scholar
• Loibl S, Poortmans P, Morrow M, et al. Breast cancer. Lancet. 2021;397(10286):1750–1769. doi: 10.1016/S0140-6736(20)32381-3.
   PubMed Web of Science ®Google Scholar
• Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727–742.
   PubMed Web of Science ®Google Scholar
• Mohammadoo‐Khorasani M, Karami Tehrani F, Atri M. Soluble guanylate cyclase isoenzymes: the expression of α1, α2, β1, and β2 subunits in the benign and malignant breast tumors. J Cell Physiol. 2020;235(2):1358–1365. doi: 10.1002/jcp.29054.
   PubMed Web of Science ®Google Scholar
• Khorasani MM, Tehrani FK, Parizadeh SMR, et al. Differential expression of alternative transcripts of soluble guanylyl cyclase, GYCY1a3 and GUCY1b3 genes, in the malignant and benign breast tumors. Nitric Oxide. 2019;83:65–71. doi: 10.1016/j.niox.2018.12.009.
   PubMed Web of Science ®Google Scholar
• Ou L, Zhang A, Cheng Y, et al. The cGAS-STING pathway: a promising immunotherapy target. Front Immunol. 2021;12:795048. doi: 10.3389/fimmu.2021.795048.
   PubMed Web of Science ®Google Scholar
• Moossavi M, Rastegar M, Moossavi SZ, et al. Molecular function of cGAS-STING in SARS-CoV-2: a novel approach to COVID-19 treatment. Biomed Res Int. 2022;2022:6189254–6189210. doi: 10.1155/2022/6189254.
   PubMed Web of Science ®Google Scholar
• Wu J, Sun L, Chen X, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science. 2013;339(6121):826–830. doi: 10.1126/science.1229963.
   PubMed Web of Science ®Google Scholar
• Khorasani M. Role of cGAS-STING in colorectal cancer: a new window for treatment strategies. Cytokine. 2024;173:156422. doi: 10.1016/j.cyto.2023.156422.
   PubMed Web of Science ®Google Scholar
• Zhang X, Bai X-C, Chen ZJ. Structures and mechanisms in the cGAS-STING innate immunity pathway. Immunity. 2020;53(1):43–53. doi: 10.1016/j.immuni.2020.05.013.
   PubMed Web of Science ®Google Scholar
• Kranzusch PJ, Lee AS-Y, Berger JM, et al. Structure of human cGAS reveals a conserved family of second-messenger enzymes in innate immunity. Cell Rep. 2013;3(5):1362–1368. doi: 10.1016/j.celrep.2013.05.008.
   PubMed Web of Science ®Google Scholar
• Civril F, Deimling T, de Oliveira Mann CC, et al. Structural mechanism of cytosolic DNA sensing by cGAS. Nature. 2013;498(7454):332–337. doi: 10.1038/nature12305.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wu J, Du F, et al. The cytosolic DNA sensor cGAS forms an oligomeric complex with DNA and undergoes switch-like conformational changes in the activation loop. Cell Rep. 2014;6(3):421–430. doi: 10.1016/j.celrep.2014.01.003.
   PubMed Web of Science ®Google Scholar
• Liu N, Pang X, Zhang H, et al. The cGAS-STING pathway in bacterial infection and bacterial immunity. Front Immunol. 2021;12:814709. doi: 10.3389/fimmu.2021.814709.
   PubMedGoogle Scholar
• Andreeva L, Hiller B, Kostrewa D, et al. cGAS senses long and HMGB/TFAM-bound U-turn DNA by forming protein–DNA ladders. Nature. 2017;549(7672):394–398. doi: 10.1038/nature23890.
   PubMed Web of Science ®Google Scholar
• Herzner A-M, Hagmann CA, Goldeck M, et al. Sequence-specific activation of the DNA sensor cGAS by Y-form DNA structures as found in primary HIV-1 cDNA. Nat Immunol. 2015;16(10):1025–1033. doi: 10.1038/ni.3267.
   PubMed Web of Science ®Google Scholar
• Du M, Chen ZJ. DNA-induced liquid phase condensation of cGAS activates innate immune signaling. Science. 2018;361(6403):704–709. doi: 10.1126/science.aat1022.
   PubMed Web of Science ®Google Scholar
• Li X, Shu C, Yi G, et al. Cyclic GMP-AMP synthase is activated by double-stranded DNA-induced oligomerization. Immunity. 2013;39(6):1019–1031. doi: 10.1016/j.immuni.2013.10.019.
   PubMed Web of Science ®Google Scholar
• Gao P, Ascano M, Wu Y, et al. Cyclic [G (2′, 5′) pA (3′, 5′) p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell. 2013;153(5):1094–1107. doi: 10.1016/j.cell.2013.04.046.
   PubMed Web of Science ®Google Scholar
• Ablasser A, Chen ZJ. cGAS in action: expanding roles in immunity and inflammation. Science. 2019;363(6431):eaat8657. doi: 10.1126/science.aat8657.
   PubMed Web of Science ®Google Scholar
• Capobianchi MR, Uleri E, Caglioti C, et al. Type I IFN family members: similarity, differences and interaction. Cytokine Growth Factor Rev. 2015;26(2):103–111. doi: 10.1016/j.cytogfr.2014.10.011.
   PubMed Web of Science ®Google Scholar
• Ferlazzo G, Pack M, Thomas D, et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A. 2004;101(47):16606–16611. doi: 10.1073/pnas.0407522101.
   PubMed Web of Science ®Google Scholar
• Fang R, Wang C, Jiang Q, et al. NEMO–IKKβ are essential for IRF3 and NF-κB activation in the cGAS–STING pathway. J Immunol. 2017;199(9):3222–3233. doi: 10.4049/jimmunol.1700699.
   PubMed Web of Science ®Google Scholar
• de Oliveira Mann CC, Orzalli MH, King DS, et al. Modular architecture of the STING C-terminal tail allows interferon and NF-κB signaling adaptation. Cell Rep. 2019;27(4):1165–1175. e5. doi: 10.1016/j.celrep.2019.03.098.
   PubMed Web of Science ®Google Scholar
• Stempel M, Chan B, Juranić Lisnić V, et al. The herpesviral antagonist m152 reveals differential activation of STING‐dependent IRF and NF‐κB signaling and STING's dual role during MCMV infection. Embo J. 2019;38(5):e100983. doi: 10.15252/embj.2018100983.
   PubMed Web of Science ®Google Scholar
• Oeckinghaus A, Ghosh S. The NF-κB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009;1(4):a000034–a000034. doi: 10.1101/cshperspect.a000034.
   PubMed Web of Science ®Google Scholar
• D'Ignazio L, Batie M, Rocha S. TNFSF14/LIGHT, a non-canonical NF-κB stimulus, induces the HIF pathway. Cells. 2018;7(8):102. doi: 10.3390/cells7080102.
   PubMed Web of Science ®Google Scholar
• House CD, Grajales V, Ozaki M, et al. IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts. BMC Cancer. 2018;18(1):595. doi: 10.1186/s12885-018-4507-2.
   PubMedGoogle Scholar
• Wan D, Jiang W, Hao J. Research advances in how the cGAS-STING pathway controls the cellular inflammatory response. Front Immunol. 2020;11:615. doi: 10.3389/fimmu.2020.00615.
   PubMed Web of Science ®Google Scholar
• Zhou W, Whiteley AT, de Oliveira Mann CC, et al. Structure of the human cGAS–DNA complex reveals enhanced control of immune surveillance. Cell. 2018;174(2):300–311. e11. doi: 10.1016/j.cell.2018.06.026.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Dai T, He X, et al. The interactions between cGAS-STING pathway and pathogens. Signal Transduct Target Ther. 2020;5(1):91. doi: 10.1038/s41392-020-0198-7.
   PubMed Web of Science ®Google Scholar
• Chen H, Sun H, You F, et al. Activation of STAT6 by STING is critical for antiviral innate immunity. Cell. 2011;147(2):436–446. doi: 10.1016/j.cell.2011.09.022.
   PubMed Web of Science ®Google Scholar
• Du S-S, Chen G-W, Yang P, et al. Radiation therapy promotes hepatocellular carcinoma immune cloaking via PD-L1 upregulation induced by cGAS-STING activation. Int J Radiat Oncol Biol Phys. 2022;112(5):1243–1255. doi: 10.1016/j.ijrobp.2021.12.162.
   PubMed Web of Science ®Google Scholar
• Harlin H, Meng Y, Peterson AC, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009;69(7):3077–3085. doi: 10.1158/0008-5472.CAN-08-2281.
   PubMed Web of Science ®Google Scholar
• Marcus A, Mao AJ, Lensink-Vasan M, et al. Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response. Immunity. 2018;49(4):754–763. e4. doi: 10.1016/j.immuni.2018.09.016.
   PubMed Web of Science ®Google Scholar
• Crasta K, Ganem NJ, Dagher R, et al. DNA breaks and chromosome pulverization from errors in mitosis. Nature. 2012;482(7383):53–58. doi: 10.1038/nature10802.
   PubMed Web of Science ®Google Scholar
• Kwon J, Bakhoum SF. The cytosolic DNA-sensing cGAS–STING pathway in cancer. Cancer Discov. 2020;10(1):26–39. doi: 10.1158/2159-8290.CD-19-0761.
   PubMed Web of Science ®Google Scholar
• Parkes EE, Walker SM, Taggart LE, et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J Natl Cancer Inst. 2017;109(1):djw199. doi: 10.1093/jnci/djw199.
   PubMedGoogle Scholar
• Fuertes MB, Kacha AK, Kline J, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J Exp Med. 2011;208(10):2005–2016. doi: 10.1084/jem.20101159.
   PubMed Web of Science ®Google Scholar
• Diamond MS, Kinder M, Matsushita H, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208(10):1989–2003. doi: 10.1084/jem.20101158.
   PubMed Web of Science ®Google Scholar
• Woo S-R, Fuertes MB, Corrales L, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41(5):830–842. doi: 10.1016/j.immuni.2014.10.017.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Sheehan KC, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol. 2005;6(7):722–729. doi: 10.1038/ni1213.
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Xu M, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41(5):843–852. doi: 10.1016/j.immuni.2014.10.019.
   PubMed Web of Science ®Google Scholar
• Li T, Chen ZJ. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J Exp Med. 2018;215(5):1287–1299. doi: 10.1084/jem.20180139.
   PubMed Web of Science ®Google Scholar
• Ka N-L, Park MK, Kim S-S, et al. NR1D1 stimulates antitumor immune responses in breast cancer by activating cGAS-STING signaling. Cancer Res. 2023;83(18):3045–3058. doi: 10.1158/0008-5472.CAN-23-0329.
   PubMed Web of Science ®Google Scholar
• Pantelidou C, Sonzogni O, De Oliveria Taveira M, et al. PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 2019;9(6):722–737. doi: 10.1158/2159-8290.CD-18-1218.
   PubMed Web of Science ®Google Scholar
• Chen M, Yu S, van der Sluis T, et al. cGAS-STING pathway expression correlates with genomic instability and immune cell infiltration in breast cancer. NPJ Breast Cancer. 2024;10(1):1. doi: 10.1038/s41523-023-00609-z.
   PubMed Web of Science ®Google Scholar
• Debnath J, Gammoh N, Ryan KM. Autophagy and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol. 2023;24(8):560–575. doi: 10.1038/s41580-023-00585-z.
   PubMed Web of Science ®Google Scholar
• Lu Q, Chen Y, Li J, et al. Crosstalk between cGAS-STING pathway and autophagy in cancer immunity. Front Immunol. 2023;14:1139595. doi: 10.3389/fimmu.2023.1139595.
   PubMed Web of Science ®Google Scholar
• Xun J, Zhang Z, Lv B, et al. A conserved ion channel function of STING mediates noncanonical autophagy and cell death. EMBO Rep. 2024;25(2):544–569.
   PubMedGoogle Scholar
• Mizushima N, Ohsumi Y, Yoshimori T. Autophagosome formation in mammalian cells. Cell Struct Funct. 2002;27(6):421–429. doi: 10.1247/csf.27.421.
   PubMed Web of Science ®Google Scholar
• Deretic V, Levine B. Autophagy balances inflammation in innate immunity. Autophagy. 2018;14(2):243–251. doi: 10.1080/15548627.2017.1402992.
   PubMed Web of Science ®Google Scholar
• Gui X, Yang H, Li T, et al. Autophagy induction via STING trafficking is a primordial function of the cGAS pathway. Nature. 2019;567(7747):262–266. doi: 10.1038/s41586-019-1006-9.
   PubMed Web of Science ®Google Scholar
• Krivega M, Stiefel CM, Karbassi S, et al. Genotoxic stress in constitutive trisomies induces autophagy and the innate immune response via the cGAS-STING pathway. Commun Biol. 2021;4(1):831. doi: 10.1038/s42003-021-02278-9.
   PubMed Web of Science ®Google Scholar
• Liu D, Wu H, Wang C, et al. STING directly activates autophagy to tune the innate immune response. Cell Death Differ. 2019;26(9):1735–1749. doi: 10.1038/s41418-018-0251-z.
   PubMed Web of Science ®Google Scholar
• Krivega M, Stiefel CM, Storchova Z. Consequences of chromosome gain: a new view on trisomy syndromes. Am J Hum Genet. 2022;109(12):2126–2140. doi: 10.1016/j.ajhg.2022.10.014.
   PubMed Web of Science ®Google Scholar
• Margolis SR, Dietzen PA, Hayes BM, et al. The cyclic dinucleotide 2′ 3′-cGAMP induces a broad antibacterial and antiviral response in the sea anemone nematostella vectensis. Proc Natl Acad Sci USA. 2021;118(51):e2109022118. doi: 10.1073/pnas.2109022118.
   PubMedGoogle Scholar
• Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–998. doi: 10.1038/ni1102-991.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Matsumura N, et al. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol. 2016;21(3):462–473. doi: 10.1007/s10147-016-0959-z.
   PubMed Web of Science ®Google Scholar
• Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. American Journal of Cancer Research. 2020;10(3):727.
   PubMed Web of Science ®Google Scholar
• Meng X, Huang Z, Teng F, et al. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev. 2015;41(10):868–876. doi: 10.1016/j.ctrv.2015.11.001.
   PubMed Web of Science ®Google Scholar
• Kuol N, Stojanovska L, Nurgali K, et al. PD-1/PD-L1 in disease. Immunotherapy. 2018;10(2):149–160. doi: 10.2217/imt-2017-0120.
   PubMed Web of Science ®Google Scholar
• Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo J. 1992;11(11):3887–3895. doi: 10.1002/j.1460-2075.1992.tb05481.x.
   PubMed Web of Science ®Google Scholar
• Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways of costimulation and inhibition of immune responses. Annu Rev Immunol. 2002;20(1):29–53. doi: 10.1146/annurev.immunol.20.091101.091806.
   PubMedGoogle Scholar
• Vibhakar R, Juan G, Traganos F, et al. Activation-induced expression of human programmed death-1 gene in T-lymphocytes. Exp Cell Res. 1997;232(1):25–28. doi: 10.1006/excr.1997.3493.
   PubMed Web of Science ®Google Scholar
• Saresella M, Rainone V, M Al-Daghri N, et al. The PD-1/PD-L1 pathway in human pathology. Curr Mol Med. 2012;12(3):259–267. doi: 10.2174/156652412799218903.
   PubMed Web of Science ®Google Scholar
• Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23(1):515–548. doi: 10.1146/annurev.immunol.23.021704.115611.
   PubMed Web of Science ®Google Scholar
• Guo ZS. The 2018 nobel prize in medicine goes to cancer immunotherapy. BMC cancer, 18(1), 1086. DOI: 10.1186/s12885-018-5020-3
   Google Scholar
• Shimauchi T, Kabashima K, Nakashima D, et al. Augmented expression of programmed death‐1 in both neoplastic and non‐neoplastic CD4+ T‐cells in adult T‐cell leukemia/lymphoma. Int J Cancer. 2007;121(12):2585–2590. doi: 10.1002/ijc.23042.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26(1):677–704. doi: 10.1146/annurev.immunol.26.021607.090331.
   PubMed Web of Science ®Google Scholar
• Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111–122. doi: 10.1016/j.immuni.2007.05.016.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–1034. doi: 10.1084/jem.192.7.1027.
   PubMed Web of Science ®Google Scholar
• Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261–268. doi: 10.1038/85330.
   PubMed Web of Science ®Google Scholar
• Rodig N, Ryan T, Allen JA, et al. Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis. Eur J Immunol. 2003;33(11):3117–3126. doi: 10.1002/eji.200324270.
   PubMed Web of Science ®Google Scholar
• Grabosch S, Bulatovic M, Zeng F, et al. Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles. Oncogene. 2019;38(13):2380–2393. doi: 10.1038/s41388-018-0581-9.
   PubMed Web of Science ®Google Scholar
• Li A, Yi M, Qin S, et al. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. J Hematol Oncol. 2019;12(1):35. doi: 10.1186/s13045-019-0721-x.
   PubMedGoogle Scholar
• Taniguchi H, Caeser R, Chavan SS, et al. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell Rep. 2022;39(7):110814. doi: 10.1016/j.celrep.2022.110814.
   PubMed Web of Science ®Google Scholar
• Manoury B, De Berardinis P. Targeted antigen delivery: bridging innate and adaptive immunity. Front Immunol. 2019;10:368. doi: 10.3389/fimmu.2019.00368.
   Google Scholar
• Hu Z, Yang Y, Fang L, et al. Insight into the dichotomous regulation of STING activation in immunotherapy. Immunopharmacol Immunotoxicol. 2021;43(2):126–137. doi: 10.1080/08923973.2021.1890118.
   PubMed Web of Science ®Google Scholar
• Cheng N. Sting activating particles for cancer immunotherapy. (Doctoral dissertation). The University of North Carolina at Chapel Hill; 2018.
   Google Scholar
• Hu Y, Manasrah BK, McGregor SM, et al. Paclitaxel induces micronucleation and activates pro-inflammatory cGAS–STING signaling in triple-negative breast cancer. Mol Cancer Ther. 2021;20(12):2553–2567. doi: 10.1158/1535-7163.MCT-21-0195.
   PubMed Web of Science ®Google Scholar
• Takahashi-Ruiz L, Fermaintt CS, Wilkinson NJ, et al. The microtubule destabilizer eribulin synergizes with STING agonists to promote antitumor efficacy in triple-negative breast cancer models. Cancers (Basel). 2022;14(23):5962. doi: 10.3390/cancers14235962.
   PubMed Web of Science ®Google Scholar
• Carlino F, Diana A, Piccolo A, et al. Immune-based therapy in triple-negative breast cancer: from molecular biology to clinical practice. Cancers (Basel). 2022;14(9):2102. doi: 10.3390/cancers14092102.
   PubMed Web of Science ®Google Scholar